Has psychiatry tamed the "ketamine tiger?" Considerations on its use for depression and anxiety

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 64, Issue , 2016, Pages 218-224

  Rasmussen, Keith G ^a  

^a MAYO CLINIC   (United States)

Author keywords

Glutamate; Ketamine; Major depression; N methyl d aspartate

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; KAINIC ACID RECEPTOR; KETAMINE; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PROPOFOL; ANALGESIC AGENT; ANTIDEPRESSANT AGENT;

ADDICTION; ANTIDEPRESSANT ACTIVITY; ARTICLE; BASAL GANGLION; BIPOLAR DEPRESSION; BLADDER DISEASE; CASE STUDY; COHORT ANALYSIS; DISEASE SEVERITY; DISSOCIATIVE DISORDER; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIZATION; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; EXCITOTOXICITY; FOLLOW UP; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR DEPRESSION; NONHUMAN; NUCLEUS ACCUMBENS; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; POSTTRAUMATIC STRESS DISORDER; PROPENSITY SCORE; PSYCHOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RELAPSE; REMISSION; SCHIZOPHRENIA; SEIZURE; SELF CONCEPT; TREATMENT RESPONSE; UNITED STATES; ANIMAL; MENTAL DISORDERS;

ANALGESICS; ANIMALS; ANTIDEPRESSIVE AGENTS; HUMANS; KETAMINE; MENTAL DISORDERS;

EID: 84941170576     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.01.002     Document Type: Article

References (80)

1. aan het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S., et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010, 67:139-145.
2. aan het Rot M., Zarate C.A., Charney D.S., Mathew S.J. Ketamine for depression: where do we go from here?. Biol Psychiatry 2012, 72:537-547.
3. Abdallah C., Fasula M., Kelmendi B., Sanacora G., Ostroff R. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J ECT 2012, 28:157-161.
4. Anger K.E. Dexmedetomidine: a review of its use for the management of pain, agitation, and delirium in the intensive care unit. Curr Pharm Des 2013, 19(22):4003-4013.
5. Benedetti F. Placebo effects: understanding the mechanisms in health and disease 2009, Oxford University Press, New York.
6. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
7. Bloch M.H., Wasylink S., Landeros-Weisenberger A., Panza K.E., Billingslea E., Leckman J.F., et al. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry 2012, 72:964-970.
8. Bremner J.D., Krystal J.H., Putnam F.W., Southwick S.M., Marmar C., Charney D.S., et al. Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 1998, 11(1):125-136.
9. Caddy C., Giaroli G., White T.P., Shergill S.S., Tracy D.K. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol 2014, 4(2):75-99.
10. Carpenter W.T. The schizophrenia ketamine challenge study debate. Biol Psychiatry 1999, 46:1081-1091.
11. Catena-Dell'Osso M., Fagiolini A., Rotella F., Baroni S., Marazziti D. Glutamate system as target for development of novel antidepressants. CNS Spectr 2013, 18(4):188-198.
12. Chilukuri H., Reddy N.P., Pathapati R.M., Manu A.N., Jollu S., Shaik A.B. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med 2014, 36(1):71-76.
13. Cho H.S., D'Souza D.C., Gueorguieva R., Perry E.B., Madonick S., Karper L.P., et al. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology (Berl) 2005, 179:136-143.
14. D'Andrea D., Sewell R.A. Transient resolution of treatment-resistant posttraumatic stress disorder following ketamine infusion (letter). Biol Psychiatry 2013, 74:e13-e14.
15. Diazgranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant depression. Arch Gen Psychiatry 2010, 67(8):793-802.
16. Diazgranados N., Ibrahim L., Brutsche N.E., Ameli R., Henter I.D., Luckenbaugh D.A., et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010, 71:1605-1611.
17. Domino E.F. Taming the ketamine tiger. Anesthesiology 2010, 113:678-686.
18. Duncan W., Sarasso S., Ferrarelli F., Selter J., Riedner B., Hajazi N., et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 2013, 16:301-311.
19. Feder A., Parides M.K., Murrough J.W., Perez A.M., Morgan J.E., Saxena S., et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. JAMA Psychiatry 2014, 71(6):681-688.
20. Ghasemi M., Kazemi M.H., Abolghasem Y., Ghasemi A., Paragomi P., Amini H., et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 2014, 215:355-361.
21. Hancock P.J., Stamford J.A. Stereospecific effects of ketamine on dopamine efflux and uptake in the rat nucleus accumbens. Br J Anaesth 1999, 82(4):603-608.
22. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009, 61:105-123.
23. Hashimoto K. The R-stereoisomer of ketamine as an alternative for ketamine treatment-resistant major depression (letter). Clin Psychopharmacol Neurosci 2014, 12(1):72-73.
24. Hillemacher T., Bleich S., Demling J., Kornhuber J. Ketamine for the treatment of depression: what about the addictive potential? (letter). Aust N Z J Psychiatry 2007, 41(9):772-773.
25. Ibrahim L., Diazgrandados N., Luckenbaugh D.A., Machado-Vieira R., Baumann J., Mallinger A.G., et al. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1155-1159.
26. Ibrahim L., Diazgrandados N., Franco-Chaves J., Brutsche N., Henter I.D., Kronstein P., et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs. add-on riluzole: results from a 4-week, double-blind, placebo controlled study. Neuropsychopharmacology 2012, 37:1526-1533.
27. Jansen K. Ketamine: dreams and realities 2001, MAPS, Sarasota, Florida.
28. Jarventausta K., Chrapek W., Kampman O., Tuohimaa K., Bjorkqvist M., Hakkinen H., et al. Effects of s-ketamine as an anesthetic adjuvant to propofol on treatment response to electroconvulsive therapy in treatment-resistant depression: a randomized pilot study. J ECT 2013, 29:158-161.
29. Johnstone R.E. A ketamine trip (letter). Anesthesiology 1973, 39(4):460-461.
30. Kellner C.H. Electroconvulsive therapy is a standard treatment; ketamine is not (yet)(Letter). Am J Psychiatry 2014, 171:796.
31. Krupitsky E.M., Grinenko A.Y. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs 1997, 29(2):165-183.
32. Krupitsky E.M., Burakov A., Romanova T., Dunaevsky I., Strassman R., Grinenko A. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat 2002, 23:273-283.
33. Krupitsky E.M., Burakov A.M., Dunaevsky I.V., Romanova T.N., Slavina T.Y., Grinenko A.Y. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 2007, 39(1):13-19.
34. Lahti A.C., Warfel D., Michaelidis T., Weiler M.A., Frey K., Tamminga C.A. Long-term outcome of patients who receive ketamine during research. Biol Psychiatry 2001, 49:869-875.
35. Lapidus K.A.B., Levitch C.F., Perez A.M., Brallier J.W., Parides M.K., Soleimani L., et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014, 10.1016/j.biopsych.2014.03.026.
36. Lara D.R., Bisol L.W., Munari L.R. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol 2013, 16(9):2111-2117.
37. Larkin G.L., Beautrais A.L. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011, 14:1127-1131.
38. Loo C.K., Katalinic N., Garfield J.B.B., Sainsbury K., Hadzi-Pavlovic D., MacPherson R. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomized controlled trial. J Affect Disord 2012, 142:233-240.
39. Luckenbaugh D.A., Niciu M.J., Ionescu D.F., Nolan N.M., Richards E.M., Brutsche N.E., et al. Do the dissociative side effects of ketamine mediate its antidepressant effects?. J Affect Disord 2014, 159:56-61.
40. Machado-Vieira R., Manji H.K., Zarate C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009, 15(5):525-539.
41. Maeng S., Zarate C.A. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007, 9(6):467-474.
42. Mathew S.J., Murrough J.W., aan het Rot M., Collins K.A., Reich D.L., Charney D.S. iluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2010, 13:71-82.
43. Middela S.P. Ketamine-induced vesicopathy: a literature review. Int J Clin Pract 2011, 65:27-30.
44. Mills I.H., Park G.R., Manara A.R., Merriman R.J. Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions. Q J Med 1998, 91:493-503.
45. Murrough J.W., Iosifescu D.V., Chang L.C., Al Jurdi R.K., Green C.E., Perez A.M., et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013, 170:1134-1142.
46. Murrough J.W., Perez A.M., Pillemer S., Stern J., Parides M.K., aan het Rot M., et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013, 74(4):250-256.
47. Niciu M.J., Luckenbaugh D.A., Ionescu D.F., Mathews D.C., Richards E.M., Zarate C.A. Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression (letter). Biol Psychiatry 2013, 74:e23-e24.
48. Niciu M.J., Grunschel B.D.G., Corlett P.R., Pittenger C.R., Bloch M.H. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J Psychopharmacol 2013, 27:651-654.
49. Okamoto N., Nakai T., Sakamoto K., Nagafusa Y., Higuchi T., Nishikawa T. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression. J ECT 2010, 26:223-227.
50. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989, 244:1360-1362.
51. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991, 254:1515-1518.
52. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999, 33:523-533.
53. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988, 24:97-99.
54. Paul R., Schaaff N., Padberg F., Moller H.-J., Frodl T. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry 2009, 10(3):241-244.
55. Perry E.B., Cramer J.A., Cho H.-S., Petrakis I.L., Karper L.P., Genovese A., et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) 2007, 192:253-260.
56. Phelps L.E., Brutsche N., Moral J.R., Luckenbaugh D.A., Manji H.K., Zarate C.A., et al. Family history of alcohol dependence and initial antidepressant response to an NMDA antagonist. Biol Psychiatry 2009, 65:181-184.
57. Price R.B., Iosifescu D., Murrough J.W., Chang L.C., Al Jurdi R.K., Iqbal S.Z., et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 2014, 31:335-343.
58. Rasmussen K.G., Ritter M.J. Some considerations of the tolerability of ketamine for ECT anesthesia: a case series and review of the literature. J ECT May 09 2014, [PMID:24820945]. 10.1097/YCT.0000000000000100.
59. Rasmussen K.G., Lineberry T.W., Galardy C.W., Kung S., Lapid M.I., Palmer B.A., et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 2013, 27(5):444-450.
60. Rasmussen K.G., Kung S., Lapid M.I., Oesterle T.S., Geske J.R., Nuttall G.A., et al. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Res 2014, 215(2):362-365. [Epub 2013 Dec 21].
61. Remerand F., Couvret C., Pourrat X., Le Tendre C., Baud A., Fusciardi J. Prevenir les hallucinations aigues associees a la perfusion intraveineuse contiue de ketamine. Therapie 2007, 62(6):499-505.
62. Rodriguez C.I., Kegeles L.S., Levinson A., Feng T., Marcus S.M., Vermes D., et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology 2013, 38:2475-2483.
63. Rush A.J. Ketamine for treatment-resistant depression: ready or not for clinical use?. Am J Psychiatry 2013, 170(10):1079-1081.
64. Rutherford B.R., Roose S.P. A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013, 170(7):723-733.
65. Rutherford B.R., Wall M.M., Glass A., Stewart J.W. The role of patient expectancy in placebo and nocebo effects in antidepressant trials. J Clin Psychiatry 2014, 75(10):1040-1046.
66. Salvadore G., Cornwell B.R., Sambataro F., Latov D., Colon-Rosario V., Carver F., et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 2010, 35:1415-1422.
67. Schatzberg A.F. A word to the wise about ketamine. Am J Psychiatry 2014, 171:262-264.
68. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20years on. Trends Pharmacol Sci 2009, 30(11):563-569.
69. Sos P., Klirova M., Novak T., Kohutova B., Horacek J., Palenicek T. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 2013, 34(3):287-293.
70. Thakurta R.G., Ray P., Kanji D., Das R., Bisui B., Singh O.P. Rapid antidepressant response with ketamine: Is it the solution to resistant depression?. Indian J Psychol Med 2012, 34(1):56-60.
71. Tso M.M., Blatchford K.L., Callado L.F., McLaughlin D.P., Stamford J.A. Stereoselective effects of ketamine on dopamine, serotonin, and noradrenaline release and uptake in rat brain slices. Neurochem Int 2004, 44(1):1-7.
72. Valentine G., Mason G.F., Gomez R., Fasula M., Watzl J., Pittman B., et al. The antidepressant effect of ketamine is not associated with changes in occipital cortex amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Res 2011, 191(2):122-127.
73. Vollenweider F.X., Leenders K.L., Oye I., Hell D., Angst J. Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography. Eur Neuropsychopharmacol 1997, 7:25-38.
74. Wang X., Chen Y., Zhou X., Liu F., Zhang T., Zhang C. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT 2012, 28:128-132.
75. Womble A. Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder. AANA J 2013, 81(2):118-119.
76. Yoosefi A., Sepheri A.S., Kargar M., Akhondzadeh S., Sadeghi M., Rafei A., et al. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder. A randomized, double-blind study. J ECT 2014, 30:15-21.
77. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
78. Zarate C.A., Singh J.B., Quiroz J.A., De Jesus G., Denicoff K.K., Luckenbaugh D.A., et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006, 163:153-155.
79. Zarate C.A., Brutsche N.E., Ibrahim L., Franco-Chaves J., Diazgranados N., Cravchik A., et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012, 71:939-946.
80. Zeilhofer H.U., Swandulla D., Geisslinger G., Brune K. Differential effects of ketamine enantiomers in NMDA receptor currents in cultured neurons. Eur J Pharmacol 1992, 17:155-158.